Danielle Workman
|
 |
As proof of the glittering allure of the obesity market, drug engineers are exploring unusual paths. The main causes of obesity -- overconsumption of fatty or sugary food and a sedentary lifestyle -- are well known. Watchdogs were wanting to see more data about adverse effects from proposed drugs, as well as drugstore further proof of benefits other than weight loss, such as lower blood pressure. But when it comes to that middle choice, the most promising class of new prescription medicines for treating long-term obesity has just been wiped out. Such questions pose a dilemma for scientists much as they do for drug regulators. Despite failures, search online pharmacy consultation for obesity drugs still looks golden PARIS Designers of anti-obesity drugstore drugs have suffered three major setbacks, but the potential reward from treating the world's fat epidemic is so great that their quest is unlikely to be deterred. Obesity is a huge and growing problem, for which people are clamouring for a quick fix. Eleven years ago, the search for an obesity drug ran into controversy when fenfluramine, an appetite suppressant, was banned in the United States help prescription drugs pain medicine over fears of its effect on the heart. But no one is going to make a drug unless they can make money out of it in the end.". Both are "very useful," said Waine. Sibutramine, sold as Reductil or Meridia, affects levels of a brain chemical called serotonin, believed to influence feelings of hunger or satiety. Sjoedin said that researchers believed that regulators, especially in the United States, were becoming increasingly demanding about proposed online pharmacy obesity drugs. The drug had never been able to gain approval in the all-important US market. This month, a study published in the journal BioMed Central found fenfluramine's damage to cardiac valves was visible seven years later. Rimonabant -- brand name Acomplia -- ran into a flurry of ever-tougher warnings from European watchdogs about potential pain pills psychiatric side effects, including depression. In the lab, at least, are potential rivals to orlistat in the field of lipase inhibitors; new neurotransmitter inhibitors that reduce appetite; and even a hydrogel pill that expands in the stomach to give a sense of fullness. But they come with a list of side effects, including, in orlistat's uriel, the risk of sudden, oily faeces. But instead of sharpening pain meds appetite -- the "munchies" associated with smoking cannabis -- they work in reverse, dulling the urge to eat. "In that respect, there is a need for drugs. Gabe Sjoedin, a specialist in obesity drugs at the University of Copenhagen, Denmark, said cannabinoid receptor antagonists had now been discredited as an approach. The three scratched drugs belong to a group called cannabinoid receptor antagonists. Even more important, are they safe. Yet it is also a complex condition, and no drug is without side effects to some degree. Treating obesity entails a limited basket of options, from lifestyle changes to drugs and gastric-bypass surgery. According to the UN's World Health Organisation (WHO), around 400 million adults were obese in 2005, and the jessie is expected to balloon to more than 700 million in 2015. "Cannabinoid receptors not only regulate the appetite, they also affect mood," he said. They take on the same target in the central nervous system as marijuana. "Obese people will be around, and I'm not sure that surgery is the solution for all them," said Sjoedin. But the molecular machinery that drives it is in many ways obscure and, it is now suspected, more complex than thought. After investing a sum rumoured to be in the hundreds of millions of euros (dollars), Sanofi-Aventis of France announced this month it was abandoning its drug rimonabant, which had stoked huge expectations at its launch in 2006. "The risk/benefit profile in this class of drugs was lower than expected for obtaining market And on Merck of the United States pulled the plug on its own experimental obesity fighter, taranabant, because of concerns about anxiety and depression at high doses. But, should these prototypes ever get the green light to go on sale, will they meet the hopes of people desperate to lose dozens of kilos in a year, rather than just a few. Also this month, the US giant Pfizer put a stop to tests of a prototype in late-stage development called CP-945,598, citing regulatory hurdles. "There are now just two drugs left, orlistat and sibutramine," said Hamil Waine, a doctor who is chairman of a British organisation, the National Obesity Forum. Orlistat, marketed as Xenical or shela, curbs absorption of fat in the intestine by blocking a pancreatic enzyme. In October, the European Medicines Agency (EMEA) recommended that rimonabant be pulled from sale in Europe.
|